The Extraordinary General Meeting of
The funds from the capital raising will be used to forcefully drive the development of the company's radionuclide therapy, Tumorad forward. Interim data from the clinical study with the company's other project, SpagoPix, have recently confirmed that the company's nanoparticles accumulate in solid human tumors, which is the basis for
'The positive interim results from the SpagoPix study and the progress of Tumorad have significantly strengthened the likelihood of success in the company's projects. The pharmaceutical project Tumorad potentially has a very high value and we want to be able to drive development forward with full force towards clinical studies, 'says
The issue is expected to raise approximately
Contact:
Tel: +46 46 811 88
Email: mats.hansen@spagonanomedical.se
(C) 2021 Electronic News Publishing, source